#GUCSM
LightNews LightNews
ascocancer.bsky.social
ICYMI: Dr. Matthew Galsky, Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses the impact of the CheckMate-901 trial results on the frontline management of mUC for #ASCODailyNews: dailynews.ascopubs.org/do/championi...
#gucsm #GUonc #GU25
February 20, 2025 at 8:23 PM
ascocancer.bsky.social
What follows frontline EV+P in advanced urothelial cancer? Experts discuss potential solutions in the absence of definitive clinical trial data: brnw.ch/21wR6dO
#GUCSM #ASCODailyNews
March 4, 2025 at 4:41 PM
ascocancer.bsky.social
ust presented at #ASCO25: AMPLITUDE is the first trial to show improved rPFS in HRR-altered mCSPC w/combo PARPi + SOC. #ASCODailyNews has more on these practice-changing results: dailynews.ascopubs.org/do/amplitude... #GUCSM #prostatecancer
June 3, 2025 at 5:43 PM
cancertherapyadv.bsky.social
Enzalutamide plus leuprolide reduces the risk of death by more than 40% in biochemically recurrent prostate cancer compared to leuprolide alone, according to research presented at #ESMO25 by @sfreedlandmd.bsky.social of @cedarssinaicancer.bsky.social. #pcsm #gucsm #ESMO2025

shorturl.at/H6RtB
October 20, 2025 at 1:30 PM
cancertherapyadv.bsky.social
Adjuvant treatment with mitomycin and BCG is as safe and effective as BCG alone for patients with NMIBC, but the combination allows for a reduction in BCG doses and may therefore help combat the BCG shortage, data presented at #ASCO25 suggest. #blcsm #gucsm shorturl.at/U0VFx
June 3, 2025 at 7:03 PM
cancertherapyadv.bsky.social
Researchers found a 9-month progression-free survival rate with the combination of fruquintinib and serplulimab for treatment-naive advanced non-clear cell renal cell carcinoma (nccRCC). @ascocancer.bsky.social #GU26 #GUCSM https://bit.ly/46APibz
Antitumor Activity Seen With Fruquintinib Plus Serplulimab in Untreated, Advanced nccRCC
The combination of fruquintinib and serplulimab has shown antitumor activity in treatment-naive advanced non-clear cell renal cell carcinoma.
bit.ly
March 2, 2026 at 5:00 PM
cancertherapyadv.bsky.social
Adjuvant radiotherapy improves locoregional failure-free survival, compared with observation, in patients with locally advanced MIBC, according to research presented at #ASTRO25. #blcsm #gucsm #astro2025
shorturl.at/kWlRH
October 3, 2025 at 3:37 PM
cancertherapyadv.bsky.social
Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma, according to phase 3 results presented at #ASCO25 by Dr Michiel Van der Heijden of @nkinl.bsky.social. #blcsm #gucsm shorturl.at/jMvR7
June 9, 2025 at 6:50 PM
cancertherapyadv.bsky.social
For pts with advanced or metastatic RCC, fruquintinib + sintilimab improves PFS compared to investigator’s choice of axilitinib or everolimus. Presented at #ESMO25 by Dr Zhenhua Liu of the West China Hospital of Sichuan University. #rccsm #gucsm #ESMO2025

shorturl.at/tzrmo
October 17, 2025 at 8:02 PM
ascocancer.bsky.social
Don’t miss out on the premier global event that has helped advance GU cancer science & transform patient care for more than 2 decades. Join us for #GU26 to be part of driving #gucsm innovations that improve patient care.

Register by Jan. 21 to save: brnw.ch/21wYTvj
January 7, 2026 at 2:47 PM
cancertherapyadv.bsky.social
The preferred treatment for gay and bisexual men with prostate cancer may differ according to preferred sexual behavior, researchers report. #pcsm #gucsm
Sexual Health Priorities Could Guide Prostate Cancer Treatment in Gay, Bisexual Men
Researchers found evidence to suggest that gay and bisexual men who prioritize insertive intercourse may experience better sexual health outcomes with external beam radiotherapy.
www.cancertherapyadvisor.com
August 13, 2025 at 8:53 PM
cancertherapyadv.bsky.social
Findings published in @jamaoncology.com suggest that cabozantinib plus atezolizumab is more effective than switching ARPI therapy in certain #mCRPC patients. shorturl.at/j32cu #pcsm #gucsm
Cabozantinib Plus Atezolizumab Appears More Effective Than Switching ARPIs in mCRPC
“To our knowledge, CONTACT-02 is the first phase 3 study of a tyrosine kinase inhibitor-immune checkpoint inhibitor combination to show a significant improvement in progression-free survival in patien...
shorturl.at
July 2, 2025 at 1:44 PM
cancertherapyadv.bsky.social
Men with #prostatecancer who closely follow the @americancancersoc.bsky.social cancer survivor guidelines after diagnosis have lower all-cause and cardiovascular mortality compared to those who do not. Published in @jamanetworkopen.com.

https://bit.ly/4nYWww9

#pcsm #gucsm
Following ACS Survivor Guidelines Reduces Mortality in Men with Prostate Cancer
Men who improve their adherence to ACS guidelines following diagnosis have a reduction in all-cause and cardiovascular mortality compared to those who maintain a low concordance with guideline recommendations.
bit.ly
September 30, 2025 at 7:09 PM
oncologynurseadv.bsky.social
Electroacupuncture to the Ciliao, Zhongliao, and Xialiao acupoints significantly accelerates time to urinary continence after radical prostatectomy for #prostatecancer, a new study finds.

https://bit.ly/4hI1yLF

#pcsm #gucsm
Electroacupuncture Accelerates Urinary Continence Return After Radical Prostatectomy - Oncology Nurse Advisor
Electrical acupuncture stimulation therapy has been shown to work on other kinds of urinary incontinence, so investigators trialed the noninvasive method for continence recovery after radical prostatectomy.
bit.ly
November 6, 2025 at 3:55 PM
cidaafonso.bsky.social
E isso, ai levam um rajadao ai depois gucsm reclamando, esses que comentam essas coisas nao acompanharam ele na casa
January 4, 2025 at 12:15 PM
hagsie.bsky.social
Here's the link to the open access paper: onlinelibrary.wiley.com/doi/full/10....

#ClinicalTrials #GUCancer #PCSM #GUCSM
How to Support Participants in Urogenital and Prostate Clinical Trials: A Qualitative Perspective
Background Clinical trials are fundamental to improving cancer treatment and clinical outcomes. Whilst clinical trials offer treatment options to affected individuals, less is known about how to bes.....
onlinelibrary.wiley.com
August 3, 2025 at 12:16 AM
ascocancer.bsky.social
Time is running out to share your high-impact data at the leading global event for GU cancers, #GU26. Help drive innovation, improve patient-centered care & contribute scientific insights. Submit an abstract today! Abstracts due Oct. 21 at 11:59 PM (ET). asco.confex.com/asco/gucs202...

#gucsm
October 13, 2025 at 1:59 PM
targetedonc.bsky.social
📍 Headed to #AUA25 in Las Vegas?
Urologic oncologists, don’t miss our exclusive preview of the most practice-changing data, breakthrough therapies, and must-see sessions in GU oncology. 🔍💡 Sign up to learn more! #gucsm
www.targetedonc.com/view/aua-202...
AUA 2025: A Sneak Peek for Community Oncologists/Urologists
At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in prostate cancer, and more.
www.targetedonc.com
April 23, 2025 at 4:09 PM
cancertherapyadv.bsky.social
In locally advanced/metastatic urothelial cancer, adding favezelimab or vibostolimab to first-line treatment with enfortumab vedotin and pembrolizumab is not associated with response or PFS, according to research presented at #GU26. #gucsm
KEYMAKER-U04: Targeted ICIs do not Improve Efficacy in Advanced Urothelial Cancer
Adding LAG-3 or TIGIT ICIs to enfortumab vedotin + pembrolizumab did not improve efficacy in pts with locally advanced or metastatic carcinoma
www.cancertherapyadvisor.com
March 1, 2026 at 12:59 AM
cancertherapyadv.bsky.social
#Prostatecancer patients with metastatic disease and low-volume primary tumors appear to have a poor prognosis.

https://bit.ly/49vP8nF

#pcsm #gucsm
Metastatic Prostate Cancer With Low-Volume Primary Tumors Has Poor Prognosis
In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary tumors.
bit.ly
January 23, 2026 at 7:11 PM
cancertherapyadv.bsky.social
In considering outcomes for evaluating how “cure” is defined in early #bladdercancer researchers concluded that use of 5-year RFS may be suitable. Published in @eururoloncol.bsky.social.

https://bit.ly/3XnxA6p

#gucsm
5-Year RFS May Define “Cure” for Patients With Early Bladder Cancer
Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure.
bit.ly
November 23, 2025 at 6:42 PM
cancertherapyadv.bsky.social
Recurrent non-muscle invasive #bladdercancer typically follows the same clinical and pathologic characteristics as the primary #tumor, even on second or third recurrences. Published in @elsevierconnect.bsky.social journal Clinical Genitourinary Cancer.

https://bit.ly/4oGEEH2

#NMIBC #gucsm
Recurrent Non-Muscle Invasive Bladder Cancer Often Matches Primary Disease
Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show direct progression to muscle-invasive or metastatic dise...
bit.ly
November 22, 2025 at 9:05 PM
cancertherapyadv.bsky.social
In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo. Presented at #ESMO25 by Dr Thomas Powles of
@qmul.bsky.social. #blcsm #gucsm #ESMO2025

shorturl.at/J32bd
October 21, 2025 at 3:29 PM
cancertherapyadv.bsky.social
First-line treatment with disitamab vedotin plus toripalimab could be a new standard for patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma, according to Dr Jun Guo, who presented these results at #ESMO25. #gucsm #blcsm #ESMO2025

shorturl.at/gyhIS
October 20, 2025 at 5:46 PM
cancertherapyadv.bsky.social
Adding perioperative enfortumab vedotin & pembrolizumab to surgical treatment can improve response and survival outcomes in patients with MIBC who are ineligible for cisplatin, according to research presented at #ESMO25. #blcsm #gucsm #esmo2025

shorturl.at/vFYcq
October 19, 2025 at 1:25 PM